Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.

about

Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of age.

P2860

Q36989067-A2E6DAB0-1121-4F46-9471-267A6E315C97

P2860

Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.

Item

http://www.wikidata.org/entity/Q41706289

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Adjuvant taxane-based chemothe ...... motherapy regimens in Ontario.

@en

type

Item

label

Adjuvant taxane-based chemothe ...... motherapy regimens in Ontario.

@en

prefLabel

Adjuvant taxane-based chemothe ...... motherapy regimens in Ontario.

@en

P1476

Adjuvant taxane-based chemothe ...... motherapy regimens in Ontario.

@en

P2093

Andrea Eisen

http://www.w3.org/2001/XMLSchema#string

Craig C Earle

http://www.w3.org/2001/XMLSchema#string

Kelvin K W Chan

http://www.w3.org/2001/XMLSchema#string

Maureen Trudeau

http://www.w3.org/2001/XMLSchema#string

Sofia Torres

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation.

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Optimal systemic therapy for early breast cancer in women: a clinical practice guideline

P2888

s10549-015-3441-0

P304

137-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-015-3441-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

152

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1007423223

http://www.w3.org/2001/XMLSchema#string

P698

26026467

http://www.w3.org/2001/XMLSchema#string

Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.

about

P2860

P2860

Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698